Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist widely utilized in the clinical management of acute migraine attacks, with or without aura, and cluster headaches. Chemically known as 3-[2-(dimethylamino)ethyl]-N,N-dimethyl-1H-indole-5-methanesulfonamide, its molecular formula is C14H21N3O2S. The substance is identified by the CAS registry number 103628-47-3. This compound represents a significant advancement in neurology, offering a targeted mechanism that constricts dilated cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, thereby alleviating severe headache pain, nausea, photophobia, and phonophobia associated with migraines.
Available in various formulations including immediate-release tablets, subcutaneous injections, nasal sprays, and oral dispersible tablets, Sumatriptan provides flexible dosing options to suit different patient needs and severity levels. The rapid onset of action, particularly with the injectable and nasal forms, makes it highly effective for patients requiring quick relief during an active attack. Unlike older analgesics, Sumatriptan does not possess significant opioid activity, reducing the risk of dependency, though it carries specific contraindications for individuals with uncontrolled hypertension, ischemic heart disease, or history of stroke due to its vasoconstrictive properties. Common side effects may include transient sensations of tingling, warmth, flushing, or dizziness at the injection site. It is crucial that patients adhere strictly to prescribed dosage limits to avoid medication-overuse headaches. As a prototype within the triptan class, Sumatriptan has set the standard for modern migraine therapy, significantly improving quality of life for millions of sufferers worldwide by providing reliable, fast-acting abortive treatment when other non-specific pain relievers fail. Its global availability underscores its status as a first-line therapeutic agent in acute migraine management protocols.